Understanding how lung cancer cells interact with their environment during treatment
Official title: The Delta Ecology of NSCLC Treatment
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10930169 · Data updated 2026-11-12
This study is looking at how non-small cell lung cancer cells interact with their surroundings in the lungs to understand what helps or hinders treatment, so we can find better ways to help patients like you respond to therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,992,935 |
| NIH project number | 5U54CA274507-02 |
| Project ID | NIH-10930169 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with specific driver mutations such as RAS, EGFR, or ALK.
✕Less likely to help
Patients with other types of lung cancer or those who do not have the targeted mutations being studied may not benefit from this research.
What this research studies
This research investigates the dynamic relationship between non-small cell lung cancer (NSCLC) cells and the lung microenvironment, focusing on how these interactions influence tumor progression and treatment responses. By analyzing changes in the ecology surrounding tumors, the study aims to identify factors that contribute to treatment resistance and success. The approach involves a combination of clinical data analysis, computer modeling, laboratory experiments, and animal studies to develop and validate predictive models for NSCLC treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with non-small cell lung cancer by addressing the factors that contribute to treatment resistance.
How similar studies have gone: Previous research has shown promise in understanding tumor microenvironments and their impact on cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.